"About a decade ago, many media outlets-including WIRED-zeroed in on a weird trend at the intersection of mental health, drug science, and Silicon Valley biohacking: microdosing, or the practice of taking a small amount of a psychedelic drug seeking not full-blown hallucinatory revels but gentler, more stable effects. Typically using psilocybin mushrooms or LSD, the archetypal microdoser sought less melting walls and open-eye kaleidoscopic visuals than boosts in mood and energy, like a gentle spring breeze blowing through the mind."
"Anecdotal reports pitched microdosing as a kind of psychedelic Swiss Army knife, providing everything from increased focus to a spiked libido and (perhaps most promisingly) lowered reported levels of depression. It was a miracle for many. Others remained wary. Could 5 percent of a dose of acid really do all that? A new, wide-ranging study by an Australian biopharma company suggests that microdosing's benefits may indeed be drastically overstated-at least when it comes to addressing symptoms of clinical depression."
About a decade ago, media attention highlighted microdosing as taking small psychedelic amounts for gentle, stable effects rather than full hallucinatory experiences. Anecdotal accounts reported improved focus, libido, energy, and reduced depression. A Phase 2B trial of 89 adults by Melbourne-based MindBio Therapeutics evaluated microdosing LSD for major depressive disorder using the Montgomery-Åsberg Depression Rating Scale over eight weeks. The trial found microdosing (4–20 μg LSD) was outperformed by placebo on depression measures. The trial is not yet published. MindBio's CEO Justin Hanka posted top-line results on LinkedIn, calling the trial highly rigorous.
Read at WIRED
Unable to calculate read time
Collection
[
|
...
]